VSNL1: A Potential Drug Target and Biomarker (G7447)

Target Name: VSNL1

NCBI ID: G7447

VSNL1

VSNL1: A Potential Drug Target and Biomarker

VSNL1 (VILIP-1) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and liver. It is a member of the VILIP gene family, which is known for its role in the regulation of ion channels and signaling pathways. The VSNL1 protein has been shown to play a significant role in the regulation of various physiological processes, including blood pressure, heart rate, and the contraction and relaxation of blood vessels.

Recent studies have suggested that VSNL1 may be a drug target in the future. This is because several compounds have been shown to interact with VSNL1 and to modulate its activity. These compounds include small molecules, such as those found in natural products, as well as drugs that are currently on the market for treating various cardiovascular and other conditions.

One of the most promising compounds that has been shown to interact with VSNL1 is called NPC1666662. This compound is a peptide that contains the amino acids Asp-21 and Asn-22 of the VSNL1 protein. Studies have shown that NPC1666662 has a significant effect on the activity of VSNL1, and that it increases the activity of the protein. This suggests that NPC1666662 may be a useful drug target for the treatment of various cardiovascular and other conditions.

Another compound that has been shown to interact with VSNL1 is called TG-412. This compound is a small molecule that is similar to the natural compound curcumin, which is a compound that is found in turmeric, a spice that is commonly used in Indian cuisine. Studies have shown that TG-412 has a significant effect on the activity of VSNL1, and that it decreases the activity of the protein. This suggests that TG-412 may be a useful drug target for the treatment of various cardiovascular and other conditions.

In addition to these compounds, several other drugs that are currently on the market have been shown to interact with VSNL1. These drugs include amlodipine, a drug that is used to treat hypertension and angina; verapamil, a drug that is used to treat hypertension, angina, and certain other conditions; and diltiazem, a drug that is used to treat hypertension, angina, and certain other conditions.

The potential benefits of these drugs, as well as the potential benefits of NPC1666662 and TG-412, are being investigated further to determine their effectiveness in treating various cardiovascular and other conditions. Clinical trials are being conducted to evaluate the safety and effectiveness of these drugs, as well as to determine the optimal dosage and timing for their use.

Overall, VSNL1 is a protein that is known for its role in the regulation of various physiological processes. The recent studies suggest that VSNL1 may be a drug target, and that several compounds, including natural products and drugs, have been shown to interact with VSNL1. Further research is needed to determine the potential benefits of these compounds and to develop safe and effective drugs that target VSNL1.

Protein Name: Visinin Like 1

Functions: Regulates (in vitro) the inhibition of rhodopsin phosphorylation in a calcium-dependent manner

The "VSNL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VSNL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets